Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Thomas

Showing results (91-100 of 217) with videos related to

Pageof 22
Sort By:
Nature Communications|February 25, 2017
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoeditingKazuyoshi Takeda, Masafumi Nakayama, Yoshihiro Hayakawa, et al.
Studies in Health Technology and Informatics|August 8, 2025
Automating Precision Oncology Literature Curation: A Decision Tree Approach Using Large Language ModelsFrank P Lin, Minh Tran, Subotheni Thavaneswaran, et al.
Nature Communications|March 5, 2024
Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensingFei Deng, Yi Li, Biyao Yang, et al.
Journal of Genetic Counseling|January 20, 2021
Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: 'Another piece of the pie'Amanda M Willis, Sian K Smith, Bettina Meiser, et al.
Journal of Community Genetics|May 26, 2015
Timing and context: important considerations in the return of genetic results to research participantsKate A McBride, Nina Hallowell, Martin H N Tattersall, et al.
Nature Reviews. Clinical Oncology|March 20, 2014
Li-Fraumeni syndrome: cancer risk assessment and clinical managementKate A McBride, Mandy L Ballinger, Emma Killick, et al.
NPJ Genomic Medicine|September 14, 2023
A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric contentRadwa Sharaf, Dexter X Jin, John Grady, et al.
Cancer Research|November 4, 2005
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug developmentCarleen Cullinane, Donna S Dorow, Maya Kansara, et al.
The Oncologist|May 8, 2025
Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapiesShirish M Gadgeel, Otto Fajardo, Fabrice Barlesi, et al.
BMC Cancer|March 10, 2011
Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancerGenni M Newnham, Matthew Conron, Sueanne McLachlan, et al.
Pageof 22

Showing results (91-100 of 217) with videos related to

Sort By:
Pageof 22
Nature Communications|February 25, 2017
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoeditingKazuyoshi Takeda, Masafumi Nakayama, Yoshihiro Hayakawa, et al.
Studies in Health Technology and Informatics|August 8, 2025
Automating Precision Oncology Literature Curation: A Decision Tree Approach Using Large Language ModelsFrank P Lin, Minh Tran, Subotheni Thavaneswaran, et al.
Nature Communications|March 5, 2024
Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensingFei Deng, Yi Li, Biyao Yang, et al.
Journal of Genetic Counseling|January 20, 2021
Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: 'Another piece of the pie'Amanda M Willis, Sian K Smith, Bettina Meiser, et al.
Journal of Community Genetics|May 26, 2015
Timing and context: important considerations in the return of genetic results to research participantsKate A McBride, Nina Hallowell, Martin H N Tattersall, et al.
Nature Reviews. Clinical Oncology|March 20, 2014
Li-Fraumeni syndrome: cancer risk assessment and clinical managementKate A McBride, Mandy L Ballinger, Emma Killick, et al.
NPJ Genomic Medicine|September 14, 2023
A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric contentRadwa Sharaf, Dexter X Jin, John Grady, et al.
Cancer Research|November 4, 2005
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug developmentCarleen Cullinane, Donna S Dorow, Maya Kansara, et al.
The Oncologist|May 8, 2025
Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapiesShirish M Gadgeel, Otto Fajardo, Fabrice Barlesi, et al.
BMC Cancer|March 10, 2011
Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancerGenni M Newnham, Matthew Conron, Sueanne McLachlan, et al.
Pageof 22